|We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. For example, here is how to disable FireFox ad content blocking while on Silicon Investor.|
A private company presently.
Viral Therapeutics is a biotechnology company involved in the production of recombinant proteins. The company utilizes a licensed yeast-based Pichia pastoris expression system for producing recombinant proteins. Currently the company's product portfolio includes several viral and cellular recombinant proteins. Several new proteins are in various stages of development. These products are being used in a number of application areas including microchip-based assays.
Viral Therapeutics will develop recombinant proteins for customer's exclusive use. The company also provides contract manufacturing services utilizing recombinant expression clones provided by customers.
Viral Therapeutics' drug discovery activities includes developing proprietary drug discovery assay systems. The company has exclusive rights to this viral fusion receptor technology. One patent on this receptor technology issued in October 1996. Other patents are pending.
Microchip-based systems for use in protein and pahtogen detection and drug discovery are under development through alliances and collaborations.
Viral Therapeutics, Inc. distributes its products through a number of internationally prominent distributors.
It is an active industry partner at the Cornell University Nanobiotechnology Center.
Hope to use the thread to track developments by this company.
|© 2019 Knight Sac Media. Data provided by IEX, Alpha Vantage, Coinbase, Binance, Fintel and CityFALCON News|